Dec. 6, 2005 — Allozyne Inc., based in Seattle, has raised approximately $3.5 million in Series A funding. The investors include MPM Capital, Arch Venture Partners, and OVP Venture Partners.
Mitchell Bloom, James Kasinger and James Burns represented the investors in this transaction.
Related Content
- Goodwin InsightsMarch 21, 2023
R&W Insurance Coverage for Healthcare Services Transactions
- AlertMarch 15, 2023
The Long (Un)Winding Road: FDA Maps Out How the End of the Public Health Emergency Will Impact its COVID-19 Policies
- AlertMarch 14, 2023
HHS to Create New Potential Medicare Pricing Models for Cell and Gene Therapy, Drugs Subject to Accelerated FDA Approval, and “High-Value” Generics
- AlertMarch 8, 2023
DOJ Revises Corporate Compliance Guidance to Take on Compensation Incentives and Communications Preservation — With a Continued Emphasis on Individual Accountability
- Goodwin InsightsMarch 2, 2023
A Recap of Resilience: Goodwin’s Life Sciences Practice
- Goodwin InsightsMarch 2, 2023
2022 Year in Review: Securities Litigation Against Life Sciences Companies
- Big Molecule WatchFebruary 28, 2023
EMA Adopts Positive Opinion for Amgen’s Eculizumab Biosimilar Candidate BEKEMV®
- AlertFebruary 28, 2023
DOJ Announces Nationwide Voluntary Corporate Self-Disclosure Policy in Effort to Standardize and Incentivize Timely Self-Reporting
- WebinarApril 27, 2023
The Inflation Reduction Act & Medicare Pricing for Drugs and Biologics
- Press ReleaseMarch 29, 2023
Kiro Raises €13.8 Million in Series A
- In the PressMarch 24, 2023
Amgen Supreme Court Arguments Aren't Just About Biology (Law360)
- Press ReleaseMarch 23, 2023
Moderna and Generation Bio Announce $76 Million Strategic Collaboration to Develop Non-Viral Genetic Medicines
- Awards and RankingsMarch 23, 2023
Nicole Daley Honored by the 2023 Massachusetts Lawyers Weekly Excellence in the Law Awards
- Awards and RankingsMarch 23, 2023
Goodwin named in Top 3 for US Private Equity Debt Deals in 2022
- In the PressMarch 23, 2023
Biopharma Industry Sharply Divided Over Supreme Court Antibody Patent Brawl (Pink Sheet)
- In the PressMarch 22, 2023
Goodwin Snags Tech and Life Sciences Litigation Trio (Commercial Dispute Resolution)